Dr. Reddy's and Immutep Enter Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa

Dr. Reddy’s Laboratories Ltd and Immutep Limited have entered into a strategic collaboration and exclusive licensing agreement for the development and commercialisation of Eftilagimod Alfa (efti) in all countries outside North America, Europe, Japan, and Greater China. Efti is a first-in-class novel immunotherapy that directly activates the immune system to fight cancer. Dr. Reddy’s will receive exclusive rights to develop and commercialise Eftilagimod Alfa in the licensed markets. Immutep will receive an upfront payment of USD 20 million and is eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5 million, plus double-digit royalties on commercial sales in these markets.